Siconolfi L
AACN Clin Issues. 1996 Aug;7(3):390-402. doi: 10.1097/00044067-199608000-00007.
The field of immunosuppression has entered a new era of sophistication, enabling investigators to selectively target specific pathways within the immune system. Recent advances offer hope that rejection after transplantation may be prevented or treated more effectively than ever before. Expanded understanding of the intracellular activities produced by immunotherapy provides a crucial foundation for clinical practice in transplant medicine. More than 25 drugs are currently under investigation for treatment of rejection, with several already undergoing clinical trials. Because they have limited actions, it is unlikely that any single agent ever will be able to control all components of the immune response. Advantages of combination therapy are, therefore, well established. Paramount to the success of this approach is the ability to select drugs with complementary mechanisms of action and without excess toxicities and unfavorable interactions. Mycophenolate mofetil (CellCept), a novel immunosuppressant for treatment of acute rejection after renal transplantation, holds great promise toward producing successful outcomes.
免疫抑制领域已进入一个更为精细的新时代，使研究人员能够选择性地针对免疫系统内的特定途径。最近的进展带来了希望，即移植后的排斥反应可能比以往任何时候都能得到更有效的预防或治疗。对免疫疗法所产生的细胞内活动的更深入了解为移植医学的临床实践提供了关键基础。目前有超过25种药物正在进行治疗排斥反应的研究，其中几种已经在进行临床试验。由于它们的作用有限，任何单一药物都不太可能控制免疫反应的所有组成部分。因此，联合治疗的优势已得到充分确立。这种方法成功的关键在于能够选择具有互补作用机制且无过多毒性和不良相互作用的药物。霉酚酸酯（骁悉），一种用于治疗肾移植后急性排斥反应的新型免疫抑制剂，有望产生成功的治疗效果。
